Revive Therapeutics Ltd.
RVV
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 24.80% | 81.67% | -36.07% | -145.14% | -94.51% |
| Total Depreciation and Amortization | -- | -100.00% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 69.05% | -99.75% | 1,319.16% | 308.93% | 1,718.75% |
| Change in Net Operating Assets | 4,016.00% | -92.31% | -102.31% | 150.18% | -40.18% |
| Cash from Operations | 54.90% | -70.68% | 83.36% | -86.83% | -75.77% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.00% | -175.34% | 198.32% | -- | -- |
| Cash from Investing | 100.00% | -175.34% | 198.32% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 67.26% | -103.09% | 0.00% | -1.31% |
| Issuance of Common Stock | -- | -- | -95.83% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | 156.95% | -216.75% | 0.00% | 1.31% |
| Cash from Financing | -- | 100.00% | -101.95% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 57.61% | -81.58% | -179.83% | 138.95% | -75.77% |